ALS drug PrimeC cuts death risk by 65%
NeuroSense's Phase 2b PARADIGM long-term follow-up reports PrimeC reduced risk of death by 65% and extended median survival by more than 14 months in 68 ALS patients; open-label extension data support a potential disease‑modifying signal as the company readies Phase 3 and regulator engagement.
Why it mattersPrimeC's Phase 2b PARADIGM 65% mortality reduction compels investors to prioritize Phase 3 funding.